Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
Farmers Insurance
US Army

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,352,684

« Back to Dashboard

Summary for Patent: 6,352,684

Title: CRC-free medicinal aerosol formulations of 1,1,1,2-tetrafluoroethane (134A) with polar adjuvant
Abstract:A medicinal aerosol formulation including 0.01-5% medicament, at least 50% by weight 1,1,1,2-tetrafluoroethane (134a), less than 5% surface active agent, and at least one compound having higher polarity than 1,1,1,2-tetrafluoroethane, and which is free of chlorofluorocarbons and propellants CHClF.sub.2, CH.sub.2 F.sub.2 and CF.sub.3 CH.sub.3.
Inventor(s): Purewal; Tarlochan S. (Leamington Spa, GB), Greenleaf; David J. (Loughborough, GB)
Assignee: Riker Laboratories Inc. (St. Paul, MN)
Application Number:09/067,346
Patent Claim Types:
see list of patent claims
Formulation; Compound;

No matches for this query

Foreign Priority and PCT Information for Patent: 6,352,684

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom88284773Dec 06, 1988

International Patent Family for Patent: 6,352,684

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany68904300► Subscribe
Germany68924540► Subscribe
Denmark595789► Subscribe
European Patent Office0372777► Subscribe
European Patent Office0499344► Subscribe
European Patent Office0653204► Subscribe
European Patent Office0995434► Subscribe
Spain2045470► Subscribe
Spain2077971► Subscribe
Canada2303601► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus